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Serotonin is elevated in risk-
genotype carriers of TCF7L2 - 
rs7903146
Andreas Leiherer1,3,4, Axel Muendlein1,3, Christoph H. Saely1,2,3, Peter fraunberger3,4 & 
Heinz Drexel1,3,5,6
The transcription factor 7-like 2 (TCF7L2) polymorphism rs7903146 is known to be tightly associated 
with an elevated risk for type 2 diabetes, whereas the molecular mechanisms remain elusive. We 
evaluated the metabolic profile of a total of 394 patients’ serum samples with respect to their 
rs7903146 genotype using targeted metabolomics in a discovery (n = 154) and a validation (n = 240) 
study. We have identified serotonin as the top metabolite being increased in carriers of the risk allele. 
Serotonin was significantly associated with the rs7903146 genotype after full adjustment including 
type 2 diabetes and further top ranked metabolites. Given the role of peripheral serotonin in metabolic 
homeostasis and type 2 diabetes, this finding provides a first hint that the well-known impact of the 
TCF7L2 polymorphism on type 2 diabetes risk may involve a serotonin-dependent pathway.
Development of type 2 diabetes is linked with dysregulated metabolism. The role of metabolic homeostasis and 
cellular sensors has recently drawn attention to peripheral serotonin which is elevated in diabetic subjects1,2. 
Although strategies interfering with serotonin synthesis are believed to hold great potential to treat type 2 diabe-
tes in humans, serotonin signalling in the periphery is immensely complex and still poorly understood1,2.
Genetic background analyses of type 2 diabetes in populations of different ethnic descent reproducibly identi-
fied single nucleotide polymorphisms (SNPs) of transcription factor 7-like 2 (TCF7L2) as one of the most impor-
tant loci to predispose carriers for type 2 diabetes3–5. Among said SNPs, variant rs7903146 showed the most 
significant association with type 2 diabetes risk3,6–9. TCF7L2, also known as TCF4, is located on chromosome 
10q25.310 and encodes a transcription factor that serves as a nuclear receptor for β-catenin in the Wingless-type 
(Wnt) signalling pathway11. Several studies have shown that TCF7L2 influences the risk of type 2 diabetes via 
impairment of β-cell function (BCF)4,8, impacting both, glucose tolerance and insulin secretion12. However, the 
exact mechanisms through which TCF7L2 and respective polymorphisms alter metabolic processes and affect the 
susceptibility to type 2 diabetes remain to be established13,14.
Integrated metabolomics and genomics hold great potential for uncovering the association of an individual 
metabolite with a single genotype and allow to generate hypotheses for mechanisms underlying the effect of a spe-
cific SNP or gene15. A previous metabolomics profiling of 41 KORA study participants carried out in conjunction 
with a glucose tolerance test revealed alterations in phospholipid metabolism in individuals with the risk TCF7L2 
genotype. To the contrary, a non-targeted metabolomics profiling of 30 TUEF study participants revealed no 
difference between homozygous carriers and non-carriers of the risk allele16.
In view of this inconsistency, we analysed the metabolic alterations in a much larger patient population, com-
prising of a discovery and a validation cohort with a total of 394 patients.
Results
Patient characteristics and subgroup analysis. In the discovery study, we randomly selected 154 from 
a total of 1660 genotyped patients including 84 subjects with the risk allele (CT/TT) and 70 carrying no risk 
allele (CC). In the validation study, we randomly selected 240 patients with 105 carrying the risk allele and 135 
patients without the risk allele. In total, 394 patients carrying either the CT/TT (n = 189) or the CC (n = 205) 
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allele combination were enrolled for metabolomics studies. Table 1 presents patient characteristics for both study 
populations with respect to TCF7L2 rs7903146.
Metabolomic profiling. Metabolite concentrations in the discovery study samples (n = 154) were analysed 
with respect to TCF7L2 rs79303146 genotype. We then compared the metabolite ratios between the CC and the 
CT/TT group. The results are summarized in Table 2 and Fig. 1. The biogenic amine serotonin was identified as 
the metabolite with the lowest ratio (0.69; p-value = 1.67 E-3), representing a 31% lower concentration of seroto-
nin in the CC-group compared to the CT/TT group. This is followed by the ceramide N-C12:0-Cer and several 
phosphatidylcholines (PC).
The second study (validation study, n = 240) was analysed accordingly. The metabolomics assay confirmed 
serotonin as the top hit with the lowest metabolite ratio (0.55) and also with the lowest p-value (3.02 E-5) of all 
metabolites (Fig. 1), followed by the amino acid arginine and a PC (Table 2).
After merging both studies (n = 394), the analysis of the merged population demonstrated again that seroto-
nin is the metabolite with lowest ratio and lowest p-value (Table 2). Finally, the merged population was also ana-
lysed according to the Significance Analysis of Microarray (SAM) approach17 (Supplementary Table 1) providing 
estimates of the false discovery rate (FDR). Serotonin was verified as the top ranked metabolite out of four with 
significantly increased concentrations (Fig. 2).
Association between the rs7903146 risk variant and serotonin. Serotonin concentration was sig-
nificantly higher in subjects with the risk allele (CT/TT) than in those carrying no risk allele (CC). In addition, it 
increased according to CC-CT-TT genotypes in patients without type 2 diabetes, but not in subjects with type 2 
diabetes (Supplementary Fig. 2). Logistic regression analyses revealed that serotonin was significantly associated 
Discovery study Validation study
CC genotype CT/TT genotype
p
CC genotype CT/TT genotype
pmean ± SD mean ± SD mean ± SD mean ± SD
Age (years) 65.93 ± 9.71 63.60 ± 9.31 0.091 65.34 ± 8.39 66.49 ± 8.43 0.255
Male sex (%) 52.9 46.4 0.427 47.6 54.8 0.268
BMI (kg/m2) 28.60 ± 5.25 28.32 ± 5.30 0.558 29.64 ± 4.79 28.78 ± 3.81 0.164
Waist circumference (cm) 102 ± 13 100 ± 13 0.232 103 ± 11 103 ± 11 0.860
Hypertension (%) 70.0 66.7 0.658 78.1 79.3 0.827
Triglycerides (mg/dl(mmol/l)) 129(1.5) ± 57(0.6) 144(1.6) ± 106(1.2) 0.755 170(1.9) ± 125(1.4) 151(1.7) ± 76(0.9) 0.674
LDL-C (mg/dl(mmol/l)) 133(3.44) ± 44(1.14) 126(3.26) ± 37(0.96) 0.306 129(3.34) ± 45(1.17) 127(3.29) ± 39(1.01) 0.878
HDL-C (mg/dl(mmol/l)) 56(1.45) ± 17(0.44) 59(1.53) ± 20(0.52) 0.291 53(1.37) ± 16(0.41) 55(1.42) ± 19(0.49) 0.645
CAD, significant (%) 48.6 47.6 0.906 45.7 58.5 0.049
Type 2 diabetes (%) 24.3 27.4 0.663 29.5 40.0 0.092
Alcohol consumption (%) 57.9 61.0 0.714 57.4 52.4 0.448
Smoking, current (%) 11.4 25.0 0.032 13.3 16.3 0.524
Glucose, fasting (mg/dl(mmol/l)) 105 (5.8) ± 202 (1.1) 116 (6.4) ± 40 (2.2) 0.236 117 (6.5) ± 46 (2.5) 122 (6.7) ± 45 (2.5) 0.087
Glucose, 2 h OGTT (mg/dl) 123 (6.8) ± 47 (2.6) 126 (7.0) ± 63 (3.5) 0.704 151 (8.4) ± 83 (4.6) 153 (8.5) ± 80 (4.4) 0.826
HbA1c (% (mmol/mol)) 5.88 (41) ± 0.57 (6) 6.18 (44) ± 0.97 (11) 0.260 6.22 (44) ± 1.21 (13) 6.43 (47) ± 1.25 (14) 0.026
Insulin (µU/ml) 12.73 ± 9.13 12.85 ± 11.19 0.676 13.96 ± 13.84 21.52 ± 77.42 0.299
eGFR (ml/min/1.73 m2) 96.37 ± 16.23 95.94 ± 17.89 0.862 94.12 ± 14.56 93.96 ± 17.48 0.604
ASA treatment (%) 70.0 73.8 0.600 73.3 62.2 0.069
Beta blocker treat. (%) 55.7 44.0 0.149 57.1 54.8 0.719
ACE inhibitor treat. (%) 40.0 27.4 0.098 28.6 31.1 0.670
ARB treat. (%) 10.0 8.3 0.720 11.4 10.4 0.794
Statin treatment (%) 35.7 46.4 0.179 51.4 48.1 0.614
Fibrate treat. (%) 0.0 1.2 0.360 2.9 3.7 0.717
Sulfonylurea treat. (%) 2.9 4.8 0.543 8.6 10.4 0.639
Biguanide treat. (%) 10.0 11.9 0.707 10.5 12.6 0.612
Glitazone treat. (%) 1.4 1.2 0.897 0.0 0.0 n.a.
Insulin treat. (%) 5.7 7.1 0.720 5.7 8.1 0.466
Antidiabetic treat. (%) 17.1 16.7 0.937 17.1 19.3 0.674
Table 1. Patient characteristics. The table presents the patient characteristics of the discovery study and of the 
validation study. Patients were separated with respect to their genotype. Data are given as means ± standard 
deviations as indicated. Hba1c is given according to DCCT and IFCC -derived units (%; mmol/mol). ACE 
denotes angiotensin converting enzyme, ARB angiotensin II receptor blocker, ASA acetyl salicylic acid, BMI 
body mass index, CAD coronary artery disease, which is defined by an angiographically determined coronary 
artery stenosis with lumen narrowing ≥50%, eGFR the estimated glomerular filtration rate, HbA1c hemoglobin 
A1c, HDL-C high density lipoprotein cholesterol, and LDL-C low density lipoprotein cholesterol.
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with the risk allele of rs7903146 even after adjustment for type 2 diabetes in the discovery study (ad. OR = 1.91 
[95% CI 1.22–3.01], p = 0.005) and the validation study (ad. OR = 2.24 [95% CI 1.47–3.41], p < 0.001) as well. 
The factor “type 2 diabetes by rs7903146” was not significantly associated with serotonin in neither of both studies 
(p = 0.910 and p = 0.830) in analysis of covariance, indicating that there is no significant impact of the diabetic 
state on the association between rs7903146 and serotonin. In further multivariate regression analyses including 
adjustment for covariates age, gender, body mass index (BMI), hypertension, significant coronary artery disease 
(sig. CAD), smoking status, and even top2 and top3 identified metabolites (arginine and PC aa C38.6, Table 2), 
serotonin remained significantly associated with rs7903146 (Fig. 3) in the discovery study (adj. OR = 1.98 [95% 
CI 1.16–3.36], p = 0.012) and in the validation study (adj. OR = 2.15 [95% CI 1.38–3.34], p = 0.001). Having 
Study Metabolite Class ratio abs ratio log2(ratio) p −log10(p)
Discovery Serotonin biogenic amine 0.693 30.7% −0.530 1.67 E-3 2.777
Discovery N-C12:0-Cer ceramide 1.241 24.1% 0.311 0.037 1.426
Discovery LPC a C18:0 lysophosphatidylcholin(acyl bond) 1.212 21.2% 0.278 0.049 1.307
Discovery PC aa C36:6 phosphatidylcholin(diacyl bond) 0.849 15.1% −0.236 0.038 1.418
Discovery PC aa C38:6 phosphatidylcholin(diacyl bond) 0.854 14.6% −0.227 0.008 2.075
Discovery H1 hexoses 0.859 14.1% −0.219 7.57 E-4 3.121
Discovery PC aa C40:6 phosphatidylcholin(diacyl bond) 0.860 14.0% −0.218 0.024 1.628
Discovery C3-OH Acylcarnitine 0.870 13.0% −0.201 0.011 1.975
Discovery PC aa C34:4 phosphatidylcholin(diacyl bond) 0.870 13.0% −0.201 0.014 1.863
Discovery C6:1 Acylcarnitine 0.871 12.9% −0.200 0.019 1.720
Discovery PC aa C36:4 phosphatidylcholin(diacyl bond) 0.904 9.6% −0.146 0.021 1.677
Discovery PC aa C38:4 phosphatidylcholin(diacyl bond) 0.906 9.4% −0.143 0.032 1.491
Validation Serotonin biogenic amine 0.553 44.7% −0.853 3.02 E-5 4.519
Validation Arg amino acid 0.864 13.6% −0.210 3.09 E-3 2.510
Validation PC aa C38:6 phosphatidylcholin(diacyl bond) 0.894 10.6% −0.162 0.015 1.837
Validation LPE a C22:6 lysophosphatidylethanolamines(acyl bond) 0.907 9.3% −0.141 3.75 E-3 2.427
Validation N-C26:1-Cer ceramide 0.908 9.2% −0.139 6.31 E-3 2.200
Validation Tyr amino acid 0.916 8.4% −0.126 0.012 1.924
Validation H1 hexoses 0.930 7.0% −0.105 0.027 1.568
Validation PE aa C36:0 phosphatidylethanolamines(diacyl bonds) 0.924 7.6% −0.114 0.028 1.549
Validation Lys amino acid 0.938 6.2% −0.093 0.029 1.537
Validation Ile amino acid 0.934 6.6% −0.098 0.043 1.366
merged Serotonin biogenic amine 0.554 44.6% −0.851 2.06 E-5 4.686
merged Arg amino acid 0.877 12.3% −0.190 1.40 E-3 2.854
merged PC aa C38:6 phosphatidylcholin(diacyl bond) 0.879 12.1% −0.186 2.96 E-3 2.529
merged PC aa C40:6 phosphatidylcholin(diacyl bond) 0.885 11.5% −0.177 0.015 1.821
merged PC aa C36:0 phosphatidylcholin(diacyl bond) 0.888 11.2% −0.172 0.037 1.438
merged H1 hexoses 0.902 9.8% −0.149 1.16 E-4 3.936
merged LPE a C22:6 lysophosphatidylethanolamines(acyl bond) 0.914 8.6% −0.130 0.010 2.020
merged PC aa C38:3 phosphatidylcholin(diacyl bond) 0.934 6.6% −0.098 0.036 1.443
merged Tyr amino acid 0.937 6.3% −0.095 0.027 1.566
merged SM C24:0 sphingomyelin 0.945 5.5% −0.082 0.041 1.388
merged PC aa C36:4 phosphatidylcholin(diacyl bond) 0.948 5.2% −0.077 0.033 1.482
merged Ile amino acid 0.949 5.1% −0.075 0.048 1.323
Table 2. Metabolites significantly associated with the TCF7L2 rs7903146 genotype. Metabolites are ranked 
according to their ratio between genotypes CC and CT/TT with a cut-off for t-test p-values of 0.05. Results are 
given for the discovery study and the validation study, and also for a merged data set after data processing and 
exclusion of outliers.
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pooled patients of both studies, a similar result was seen in the merged study population (adj. OR = 1.49 [95% 
CI 1.18–1.89], p = 0.001). In addition, even if patients with type 2 diabetes (n = 125) were excluded from anal-
ysis, the risk allele of rs7903146 remained significantly associated with serotonin in the fully adjusted model 
(adj. OR = 1.51 [95% CI 1.14–2.01], p = 0.005) and this was also true in the discovery (adj. OR = 2.15 [95% 
CI 1.16–3.97], p = 0.015) and validation study (adj. OR = 2.07 [95% CI 1.23–3.51], p = 0.007); Supplementary 
Fig. 3). Furthermore, not even the exclusion of patients being treated with serotonin-impacting drugs (n = 44, 
Supplementary Table 2) did abrogate the significant association between the risk genotype and serotonin (pooled 
adj. OR = 1.34 [95% CI 1.03–1.73], p = 0.027; discovery study adj. OR = 1.80 [95% CI 1.00–3.22], p = 0.049; vali-
dation study adj. OR = 1.92 [95% CI 1.19–3.10], p = 0.008; Supplementary Fig. 4).
With respect to the tryptophan (Trp) and serotonin metabolism (Fig. 4), we also compared the Trp to sero-
tonin and the Trp to kynurenine ratio. We found a significant association between the Trp-serotonin ratio and 
rs7903146 but not between the Trp-kynurenine ratio and rs7903146 in the discovery study and the validation 
study, and also in the merged population (Supplementary Fig. 5).
Validation of association between serotonin and type 2 diabetes. We went on to verify whether 
serotonin concentrations were also elevated in diabetic subjects of our study population as reported previously by 
Figure 1. Volcano plot. The volcano plot depicts the combination of metabolite ratios of wildtype and risk 
allele carriers (ratio) and t-test p-values (p) in the discovery study (A) and the validation study (B). The x-axis 
represents log2 (ratio), the Y-axis is −log10 (p), based on raw p-values. The black horizontal line represents 
threshold for p-value (0.05).
Figure 2. SAM plot. The plot depicts the observed relative differences versus the expected relative differences 
estimated by data permutation. The solid diagonal line indicates where these two measures are the same. The 
dotted lines are drawn at a distance of delta from the solid line. With a given delta of 1.0, four metabolites were 
identified to be significantly increased in the risk genotype (highlighted in green) according to an FDR of 3.59 
E-2. Metabolites are listed in Supplementary Table 1.
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others1,2. We could confirm that serotonin concentration as determined by mass spectroscopy was significantly 
higher in diabetic patients (n = 125) than in non-diabetic patients of our merged population (n = 269; 0.112 vs. 
0.074 µmol/l, p = 0.013). In addition, we also compared the Trp to serotonin, the Trp to kynurenine ratio, and the 
Figure 3. Association between rs7903146 genotype and serotonin. The forest plot depicts the adjusted odds 
ratios and 95% CI derived from binary logistic regression analysis for the association between TCF7L2 
rs7903146 genotype and serum serotonin concentration as a continuous variable with stepwise adjustment. 
Adjustment model 1, a univariate model, represents the association between the genotype and serotonin. Model 
2 represents the association between the genotype and serotonin with the type 2 diabetes status as covariate. 
Model 3 accounts for the parameters included in model 2 and, in addition, the covariates age, gender, and body 
mass index. Model 4 accounts for the parameters included in model 3 and, in addition, the hypertension status, 
the sig. CAD status, and the current smoking status. Model 5 accounts for the parameters included in model 4 
and, in addition, arginine and the phosphatidylcholine PC aa C38:6. DS denotes discovery study, VS validation 
study.
Figure 4. Main metabolic pathways in serotonin biosynthesis. AADC denotes aromatic L-amino-acid 
decarboxylase, AANAT aralkylamine N-acetyltransferase, ALDH aldehyde dehydrogenase, ASMT 
N-acetylserotonin O-methyltransferase, IDO indoleamine-pyrrole 2,3 dioxygenase, KFA Kynurenine 
formamidase, MAO Monoaminooxidase, TDO tryptophan 2,3 dioxygenase, TPH represents tryptophane 
hydroxylase.
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kynurenine concentration in diabetic and non-diabetic patients. Coherently, the Trp-serotonin ratio was signifi-
cantly lower in diabetic than in non-diabetic patients (1.70 E + 3 vs. 2.21 E + 3, p = 0.011), whereas no significant 
difference was seen with respect to the Trp-kynurenine ratio (14.9 vs. 15.2, p = 0.306) or the kynurenine concen-
tration only (4.5 vs. 4.4 µmol/l, p = 0.466).
Validation of association between the rs7903146 risk variant and type 2 diabetes. Analysing 
all 1660 genotyped patients in the total study, we found that risk allele carriers (n = 872) had a significantly higher 
fasting glucose (115.8 vs.109.3 mg/dl, p = 0.007), post-challenge glucose (147.1 vs.135.2 mg/dl, p = 0.036), and 
HbA1c (6.2% (44 mmol/mol) vs. 6.0% (42 mmol/mol), p < 0.001), than patients who were (C/C) homozygous 
(n = 788). In accordance with previous data3,6–9, the prevalence of type 2 diabetes was significantly higher in CT/
TT-carriers than in CC-carriers (30.8 vs. 25.8%, p = 0.022). However, fasting insulin was not significantly dif-
ferent between CT/TT- and CC-carriers (12.6 vs. 12.3 µU/ml, p = 0.229). Furthermore, there was no significant 
difference with respect to BMI (27.4 vs. 27.7, p = 0.358), triglycerides (145 mg/dl (1.6 mmol/L) vs. 154 mg/dl 
(1.7 mmol/L), p = 0.099), LDL-C (128 mg/dl (3.30 mmol/L) vs. 130 mg/dl (3.36 mmol/L), p = 0.199), or HDL-C 
(54 mg/dl (1.39 mmol/L) vs. 53 mg/dl (1.37 mmol/L), p = 0.273).
Genotyping of the TCF7L2 gene locus. As genome wide association studies (GWAS) with serotonin 
as phenotype did not identify a genomic region with genome-wide significance, we focused on the locus of the 
TCF7L2 gene (position 112.910 kb and 113.278 kb (GRCh38.7); chromosome 10) and obtained a hint for an 
association between the TCF7L2 gene and serotonin concentration (Supplementary Fig. 6). We thus analysed the 
TCF7L2 gene locus which comprises 286 SNPs on the Cardio-Metabo chip (Illumina). After Pruning, 130 SNPs 
remained and were used in tagging analysis (Supplementary Fig. 7). Tagging analysis with a threshold of r2 < 0.9 
for linkage disequilibrium (LD) revealed 19 unlinked SNPs, which cover the mentioned genomic region. These 
SNPs were analysed, and we found that 8 of these 19 SNPs were significantly associated with serotonin after FDR 
correction for multiple testing (Supplementary Table 3).
Promotor analysis of genes involved in serotonin metabolism. In order to analyse promotors 
of genes involved in serotonin biosynthesis and metabolism (Fig. 4), we applied in silico binding site predic-
tion for transcription factor TCF7L2 using the Match search algorithm18 together with the TRANSFAC data-
base. Proximal promoter sequences of tryptophan hydroxylase 1 (TPH1), tryptophan 2,3-dioxygenase 2 
(TDO2), indoleamine-pyrrole 2,3-dioxygenase 1 and 2 (IDO1, IDO2), aromatic L-amino acid decarboxylase 
(AADC), monoamine oxidases A and B (MAO-A, MAO-B), aldehyde dehydrogenase 2 (ALDH2), aralkylamine 
N-acetyltransferase (AANAT), N-acetylserotonin O-methyltransferase (ASMT), were analysed. By doing so 
we applied a user-defined profile of high quality matrices (Supplementary Table 4). We could identify several 
TCF7L2-specific binding sites in every promoter (Supplementary Fig. 8) including the TCF7L2 promoter, for 
which binding is proven by chromatin immunoprecipitation19.
Discussion
TCF7L2 polymorphism rs7903146 is associated with serotonin and glycerolphospholipid con-
centration in targeted metabolomics. In the present study, we have applied targeted metabolomics on 
154 serum samples in a discovery study and replicated this analysis 14 months later using 240 samples in a valida-
tion study. In both studies, we found that circulating serotonin was the metabolite with the highest values in indi-
viduals with the type 2 diabetes risk variant rs7903146 in TCF7L2 compared to patients without the variant. We 
also found that further common variants within the genomic region of TCF7L2 gene, which are not genetically 
linked with rs7903146, were significantly associated with serum serotonin concentrations. In addition, serotonin 
concentration was significantly associated with the prevalence of type 2 diabetes. Of note, the association between 
serotonin and rs7903146 was independent from patients’ type 2 diabetes status and was also found in patients 
without type 2 diabetes.
Whereas a previous non-targeted metabolomics assay did not reveal any metabolic difference between 
rs7903146 genotypes in 30 participants16, targeted metabolomics, given its methodical differences20, could 
demonstrate alterations of phospholipid metabolism in response to challenge tests in subjects carrying the 
TCF7L2 risk allele (n = 17) compared to those without the risk allele (n = 24)21. These results have been suggested 
to reflect a genotype-mediated link to early metabolic abnormalities that precede the development of disturbed 
glucose tolerance21. In our study, comprising nearly 400 participants, we have identified -besides serotonin - sev-
eral glycerolphospholipids to be significantly associated with rs7903146 as well, thus corroborating these previous 
data.
TCF7L2 is part of the Wnt signalling and polymorphisms in TCF7L2 are associated with type 2 
diabetes. TCF7L2 is a major transcription factor of the canonical Wnt signalling pathway. The key effector 
of the Wnt signalling pathway is the bipartite transcription factor β-catenin/TCF. It is formed by free β-catenin 
and a member of the TCF protein family, which includes TCF7L222. The prerequisite for Wnt signalling is the 
binding of a Wnt ligand to the Frizzled receptor and the co-receptor LDL receptor-related protein 5 (LRP5) or 
LRP6, preventing degradation of β-catenin and allowing formation of the β-catenin/TCF complex and activation 
of downstream target genes22.
Wnt signalling is involved in regulating numerous processes including metabolic homeostasis in general, bone 
formation23, hormone gene expression and pancreatic β-cell proliferation24. Particularly, TCF7L2 is known as a 
major type 2 diabetes susceptibility gene3,7, which is also linked to diabetic coronary atherosclerosis9. A recent 
GWAS comprising 62,892 type 2 diabetes cases and 596,424 controls of European ancestry, identified polymor-
phism rs7903146 as the variant with the highest association, out of 16 million genetic variants25. Thus the overall 
mechanism, how transcription factor TCF7L2 and in particular rs7903146 impacts the metabolic state and is 
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associated with diabetes has been intensively discussed in the past. Although there are some hypotheses based on 
incretin, glucose disposal, and insulin signalling data4,22,26,27, the connecting mechanism between diabetes and 
TCF7L2 still remained far from being thoroughly understood22.
More recently, the rs7903146 variant in the TCF7L2 gene has been reported to increase the risk of prediabetes 
and type 2 diabetes in obese subjects by declining insulin sensitivity and β-cell function, and also predicts the 
development of prediabetes and diabetes over time28. Reviewing 153 meta-analyses, Amare et al. found a genetic 
overlap between cardiometabolic diseases and mood disorders in 24 genes, including TCF7L229. Pathway analysis 
identified serotonin receptor signalling consistently being within the top ranked hits29. Thus the identification of 
elevated serotonin in rs7903146 CT/TT allele carriers in our study offers a new way to explain the link between 
TCF7L2 and diabetes.
Serotonin is elevated in diabetes. Serotonin is synthesized from tryptophan, the least abundant essen-
tial amino acid in mammals. It is regulated by the rate limiting enzyme tryptophan hydroxylase (TPH). THP is 
not only found in the brain (TPH2) but also in enterochromaffin cells in the intestine (TPH1)30. Biosynthesis 
of serotonin is thus dependent on dietary tryptophane intake and also on the kynurenine pathway as there is a 
balance between the kynurenine and serotonin pathways31 (Fig. 4). Similarly, kynurenine concentration is influ-
enced by tryptophan intake as well. Therefore, the kynurenine to tryptophan ratio is better suited to represent 
tryptophan catabolism than the absolute concentration of kynurenine32. Serotonin, on the other hand, can be 
transformed to melatonin or catabolised to inactive molecules found in urine. It is a physiological modulator 
and thus impacts of several processes including mood and sleep, regulation of appetite, body temperature, and 
metabolism29. Lorcaserin, a brain-specific serotonin-agonist33 has recently demonstrated its anorectic potential 
promoting weight loss with no excess in cardiovascular events but a reduced rate of new onset or progressive 
renal impairment in the CAMELLIA-TIMI 61 Trial34,35. However, serotonin not only acts in the brain. Ninety-five 
percent of serotonin is produced in the periphery2, in particular in the gut36 and its synthesis is modulated by gut 
microbiota37. Of note, serotonin does not pass the blood-brain barrier and the two major pools, brain and periph-
ery, remain separated2. In the periphery, it promotes inflammation38, inhibits activity of brown adipose tissue, 
and is elevated in obesity39. Moreover, it regulates glucose homeostasis, hepatic gluconeogenesis, and mobiliza-
tion of hepatic free fatty acids40, and thus has direct implication for metabolic disorders such as diabetes41. Apart 
from the intestine, serotonin is also synthesized in pancreatic β-cells42, stored along with insulin-granules, and is 
released upon glucose stimulation43. Serotonin is also a strong paracrine regulator of α-cell activity44. However, 
the mechanisms that drive altered serotonin signalling in the pancreatic cells remain unclear41.
Nevertheless, with respect to its concentration in the circulation, serotonin is known to be increased in indi-
viduals with diabetes41. In accordance, our study found significantly higher serotonin concentrations in diabetic 
patients compared to patients without diabetes. Moreover, there is a well-known increased risk of diabetes in 
patients suffering from depression and taking e.g. serotonin reuptake inhibitors increasing the extracellular level 
of serotonin and targeting serotonin signalling45. However, we could rule out the confounding of our results by 
serotonin-impacting medication in a subgroup analysis.
TCF7L2 rs7903146 polymorphism is associated with serotonin, independent from diabetes, 
but it is not associated with kynurenine. We found that the association between rs7903146 and ser-
otonin is independent of and, therefrom not confounded by the diabetic status of the patients. This association 
was found both in the discovery study and the validation study. In addition, we found that 8 of 19 tagging SNPs 
covering the TCF7L2 locus were significantly associated with serotonin, even after correction for multiple testing.
We also demonstrated that this association was specific for serotonin and did not apply to the alternative 
tryptophan metabolite kynurenine, precluding upstream effects e.g. tryptophan intake. Thus, the higher serotonin 
concentration probably results from decreased processing of serotonin.
In that context, we also found several binding sites for TCF7L2 in genes involved in serotonin biosynthesis. 
However, it has to be mentioned that validity of in silico only data is quite limited; thus, this is no proof for a direct 
binding of the transcription factor TCF7L2 to respective promoter sequences, but at the same time it precludes 
that direct binding is prevented. As there are no experimental data available, apart from binding of TCF7L2 to its 
own promoter region19, these genes may be candidates for functional studies in the future.
Wnt signalling impacts serotonin concentration and thus may be a missing link between pol-
ymorphisms in TCF7L2 and diabetes. The present study’s data have clearly demonstrated that there is a 
significant association between the major transcription factor of the Wnt signalling pathway, TCF7L2, and sero-
tonin concentration. Thus our findings are, in part, corroborated by previous data in the context of bone turnover, 
suggesting as well that Wnt signalling is most likely involved in serotonin expression46. This is also in line with 
more recent findings in enteroendocrine cell lineages, in which serotonin biosynthesis has been demonstrated 
to be regulated by LMX1A47. LMX1A, on the other hand, is regulated by Wnt signalling and builds an autoreg-
ulatory loop with Wnt148,49 during embryogenesis. Taken together all these data support the hypothesis that 
serotonin might be involved, at least in part, in the impact of Wnt signalling on metabolic homeostasis and type 
2 diabetes22. These data provide a possible link between polymorphisms in TCF7L2 and serotonin and suggest 
genes involved in serotonin metabolism as candidate genes for functional studies in the future.
Limitations and open questions. The current study has its limitations. It has to be mentioned that there 
are further mechanism by which TCF7L2 might impact the diabetes risk, and some of these mechanism may 
be independent from Wnt signalling22. Apart from that, there are also other mechanisms probably contributing 
to and being involved in the regulation of the serotonin level and development of diabetes e.g. the gut microbi-
ome41 or mutation of the tryptophan hydroxylase gene43. Moreover, an isotope labelling cell experiment would be 
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well-suited for confirming that serotonin is from tryptophane in cells with rs7903146 genotype and that serotonin 
production in cells with rs7903146 is different from that seen in wt cells. Second, our study patients are a selected 
group of coronary patients and thus, do not necessarily reflect the general population. However, this study popu-
lation, which is at a very high risk of cardiovascular complications, is clinically very important.
conclusion
This study is currently the largest investigation on the impact of rs7903146 on the metabolome. It provides a first 
hint that the well-known impact of the TCF7L2 polymorphism rs7903146 on diabetes risk may, at least in part, 
be dependent on serotonin regulation mediated by the Wnt signalling pathway. Thus these findings may help to 
shed light on the mechanism that increases circulating serotonin in the context of metabolic dysfunction and 
type 2 diabetes, which has been obscure until now. Finally, the presented link between TCF7L2 and serotonin 
is biologically plausible, and the association between TCF7L2 and diabetes on the one hand and the association 
between serotonin and diabetes on the other hand are already known. Our results should foster more interest into 
the described hypothesis.
Methods
Study subjects and metabolomic analysis. For the discovery phase study in December 2009, we ran-
domly and consecutively selected and analysed 154 patient samples from a total study population of 1660 angiog-
raphied and genotyped patients of Caucasian origin which have been recruited between 1999 and 2009. Further 
details are given in the supplementary part or were reported previously9. For the validation study, 240 samples 
were consecutively enrolled from the same total study population and analysed in February 2011.
For both the metabolomics assays, we applied a targeted quantitative metabolomic approach to analyse the 
serum samples (BIOCRATES Life Sciences AG, Austria) using liquid chromatography (LC), - mass spectroscopy 
(MS), and flow injection analysis (FIA) - MS respectively. In total, 539 compounds were analysed in 394 serum 
samples. For data pre-processing, metabolites with missing values of at least 20% were removed. Remaining 
missing values were imputed by half of the minimum positive value in the original data set (program default 
setting). After that, non-informative variables of very small values, close to baseline or detection limit, were 
detected according to median and filtered. Then, data were normalised by the reference feature BMI due to its 
association with rs79031464, followed by a transformation (log2) to correct for heteroscedasticity, and finally by 
Pareto-scaling to minimize the effect of small noisy variables. Outlier detection was performed using principal 
component analysis (PCA, Supplementary Figure 1) and respective samples (n = 5 in the discovery study; n = 1 
in the validation study) were excluded from further metabolomic analysis. Multiple testing was addressed by 
calculating q-values50 and using significance analysis of microarrays (SAM)17. Data were finally analysed using 
MetaboAnalyst software version 3.0 (http://www.metaboanalyst.ca/).
Basic laboratory tests, genotyping, and transcription factor analysis. A detailed description of 
laboratory, genotyping and transcription factor analyses is given in the supplemental methods section. In short, 
venous blood samples were collected from fasted subjects and basic laboratory measurements were immedi-
ately performed. DNA was extracted from all 1660 patient samples and SNPs in cardiovascular and metabolism 
genes were characterised using the Illumina Cardio-Metabo chip technology (Illumina Inc., San Diego, CA)51. 
Transcription factor analysis was done in silico applying the Match search algorithm18 in combination with the 
professional version of TRANSFAC database (release 2018.2), implemented in the geneXplain platform (http://
genexplain.com/genexplain-platform/; GeneXplain, Wolfenbüttel, Germany).
Statistics. Differences in baseline characteristics were tested for statistical significance with the Chi-squared 
tests for categorical and Jonckheere-Terpstra tests for continuous variables, respectively. Correlation analyses were 
performed calculating non-parametric Spearman rank correlation coefficients. For comparing continuous or cat-
egorical variables we used Wilcoxon and McNemar tests, respectively. T-test was used only in terms of metabo-
lomic analysis of normalised and logarithmised (log2) data. For logistic regression, data were z-transformed and 
data coming from LC-MS and FIA-MS were logarithmised (log2) before transformation, respectively. All results 
are given as mean ± standard deviation (SD); p-values < 0.05 were considered significant, if not otherwise speci-
fied (GWAs). All data were analysed according to complete-case analysis.
All statistical analyses were performed with SPSS 21.0, SPSS Sample Power 3.0 (SPSS, Inc., Chicago, IL), 
PLINK version 1.07; (http://zzz.bwh.harvard.edu/plink/download.shtml), and R statistical software version 3.2.3 
(http://www.r-project.org).
The present study was performed in accordance with the Declaration of Helsinki. The study, all including 
research, and all methods adhere to relevant guidelines and regulations and have been approved by the Ethics 
Committee of the University of Innsbruck. Written informed consent was given by all participants.
Prior presentation. Data have been presented during the 78th ADA scientific sessions in Orlando.
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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